https://www.selleckchem.com/products/Axitinib.html
miR-34a-5p mediates growth, migration and other malignant behaviors in CC by regulating CDC25A. Bevacizumab, an anti-angiogenic agent targeting vascular endothelial growth factor (VEGF), is widely used for the treatment of ovarian cancer. However, no predictive biomarkers of clinical outcome for bevacizumab therapy have been identified. Adipose tissue secretes various growth factors, including VEGF, which may neutralize bevacizumab and attenuate its effects. Therefore, we evaluated whether obesity is a predictive biomarker of clinical
Me gusta
Comentario
Compartir
